

MALAYSIA

Warta Kerajaan
SERI PADUKA BAGINDA
DITERBITKAN DENGAN KUASA

HIS MAJESTY'S GOVERNMENT GAZETTE
PUBLISHED BY AUTHORITY

Jil. 52
No. 17

21hb Ogos 2008

TAMBAHAN No. 88
PERUNDANGAN (A)

P.U. (A) 277.

AKTA PENGANGKUTAN JALAN 1987

PERINTAH PENGANGKUTAN JALAN (LARANGAN PENGGUNAAN JALAN)
(WILAYAH PERSEKUTUAN PUTRAJAYA) 2008

BAHAWASANYA melalui P.U. (B) 265 yang disiarkan pada 3 Julai 2008, notis telah diberi mengenai cadangan untuk membuat suatu perintah di bawah subseksyen 70(1) dan (2) Akta Pengangkutan Jalan 1987 [*Akta 333*]:

DAN BAHAWASANYA tiada apa-apa bantahan yang diterima oleh Perbadanan Putrajaya terhadap pembuatan perintah tersebut:

MAKA OLEH YANG DEMIKIAN, pada menjalankan kuasa yang diberikan oleh subseksyen 70(1) dan (2) Akta, Perbadanan Putrajaya, setelah berunding dengan Ketua Pengarah Pengangkutan Jalan dan setelah memberi pertimbangan kepada perkara-perkara yang disebut dalam subseksyen 70(2) Akta, membuat perintah yang berikut:

Nama dan permulaan kuat kuasa

1. (1) Perintah ini bolehlah dinamakan **Perintah Pengangkutan Jalan (Larangan Penggunaan Jalan) (Wilayah Persekutuan Putrajaya) 2008**.

(2) Perintah ini mula berkuat kuasa pada 15 Oktober 2008.

Larangan

2. Pemanduan atau penggunaan kelas kenderaan yang diperihalkan dalam Jadual Pertama ke mana-mana arah di atas mana-mana bahagian jalan di Persiaran Utara dan Persiaran Timur yang ditunjukkan dalam peta dalam Jadual Kedua dilarang.

Pengecualian


3. Walau apa pun peruntukan-peruntukan Perintah ini, pengecualian diberikan bagi maksud dan hal keadaan yang dinyatakan dalam Jadual Ketiga.

JADUAL PERTAMA**KELAS KENDERAAN**

1. Kenderaan orang cacat, iaitu, kenderaan motor yang mempunyai berat tanpa muatannya tidak melebihi dua ratus lima puluh kilogram, yang direka bentuk dan dibina khas atau disesuaikan bagi kegunaan seseorang yang mengalami kecacatan atau ketidakupayaan jasmani dan semata-mata digunakan oleh orang itu;
2. Motosikal, iaitu, kenderaan motor yang mempunyai kurang daripada empat roda, dan yang berat tanpa muatannya tidak melebihi empat ratus lima puluh kilogram.

JADUAL KEDUA
[Perenggan 2]

PETA PERSIARAN UTARA DAN PERSIARAN TIMUR



JADUAL KETIGA

PENGECUALIAN

1. Mana-mana motosikal yang dimiliki oleh Kerajaan untuk mengiringi kenderaan yang membawa Yang di-Pertuan Agong atau Raja Permaisuri Agong, Raja-Raja atau Permaisuri-Permaisuri Baginda, Yang di-Pertua Negeri bagi Negeri-Negeri Melaka, Pulau Pinang, Sabah dan Sarawak atau isteri-isteri mereka, Dato'-Dato' Undang Negeri Sembilan atau Tengku Besar Tampin atau isteri-isteri mereka, Tengku Mahkota atau Raja Muda mana-mana Negeri atau isteri-isteri mereka, Raja Di-Hilir Perak atau isterinya, atau mana-mana pembesar asing yang datang melawat.
2. Mana-mana motosikal yang dimiliki oleh Kerajaan untuk mengiringi mana-mana kenderaan Kerajaan yang membawa Perdana Menteri atau Timbalan Perdana Menteri.

Dibuat 25 Julai 2008

[PPj/UNDANG(A) 8-5; PN(PU²)460/LIV]

TAN SRI SAMSUDIN BIN OSMAN

Presiden

Perbadanan Putrajaya

ROAD TRANSPORT ACT 1987

ROAD TRANSPORT (PROHIBITION OF USE OF ROAD)
(FEDERAL TERRITORY OF PUTRAJAYA) ORDER 2008

WHEREAS by P.U. (B) 265 published on 3 July 2008, notice was given of the intention to make an order under subsections 70(1) and (2) of the Road Transport Act 1987 [*Act 333*]:

AND WHEREAS no objection was received by the Perbadanan Putrajaya against the making of such an order:

NOW THEREFORE, in exercise of the powers conferred by subsections 70(1) and (2) of the Act, the Perbadanan Putrajaya, after consultation with the Director General of Road Transport and after taking into consideration the matters referred to in subsection 70(2) of the Act, makes the following order:

Citation and commencement

1. (1) This order may be cited as the **Road Transport (Prohibition of Use of Road) (Federal Territory of Putrajaya) Order 2008**.

- (2) This Order comes into operation on 15 October 2008.

Prohibition

2. The riding or use of the class of vehicles as described in the First Schedule in either direction on any part of the road of Persiaran Utara and Persiaran Timur as shown on the map in the Second Schedule is prohibited.

Exemptions

3. Notwithstanding the provisions of this Order, exemption is given for the purpose and the events as specified in the Third Schedule.


FIRST SCHEDULE

CLASS OF VEHICLES

1. Invalid carriages, that is to say, motor vehicles, the unladen weight of which does not exceed two hundred and fifty kilogrammes, which are specially designed and constructed or adapted for the use of a person suffering from some physical defect or disability and used solely by such person;
2. Motorcycles, that is to say, motor vehicles with less than four wheels, and the unladen weight of which does not exceed four hundred and fifty kilogrammes.

SECOND SCHEDULE
[Paragraph 2]

MAP OF PERSIARAN UTARA AND PERSIARAN TIMUR



THIRD SCHEDULE

EXEMPTIONS

1. Any motorcycle belonging to the Government used to escort vehicles carrying The Yang di-Pertuan Agong or The Raja Permaisuri Agong, The Rulers or their consorts, The Yang di-Pertua Negeri of the States of Malacca, Penang, Sabah and Sarawak or their wives, the Dato'-Dato' Undang Negeri Sembilan or The Tengku Besar Tampin or their wives, The Tengku Mahkota or The Raja Muda of any State or their wives, The Raja Di-Hilir of Perak or his wife, or any visiting foreign dignitary.
2. Any motorcycle belonging to the Government used to escort any Government vehicle carrying the Prime Minister or the Deputy Prime Minister.

Made 25 July 2008

[PPj/UNDANG(A) 8-5; PN(PU²)460/LIV]

TAN SRI SAMSUDIN BIN OSMAN
President
Perbadanan Putrajaya

P.U. (A) 278.

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN JADUAL KETIGA) 2008

PADA menjalankan kuasa yang diberikan oleh subseksyen 30(2) Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Jadual Ketiga) 2008**.

Pindaan Jadual Ketiga

2. Jadual Ketiga kepada Akta Racun 1952, dipinda dalam perenggan 1 dengan memasukkan selepas butiran “Buprenorphine” butiran “Bupropion”.

Dibuat 21 Julai 2008

[KK(R)608(14); PN(PU²)172/IX]

DATO' LIOW TIONG LAI
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF THIRD SCHEDULE) ORDER 2008

IN exercise of the powers conferred by subsection 30(2) of the Poisons Act 1952 [*Act 366*], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Third Schedule) Order 2008**.

Amendment of Third Schedule

2. The Third Schedule to the Poisons Act 1952, is amended in paragraph 1 by inserting after the item “Buprenorphine” the item “Bupropion”.

Made 21 July 2008

[KK(R)608(14); PN(PU²)172/IX]

DATO' LIOW TIONG LAI
Minister of Health

P.U. (A) 279.

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2008

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) 2008**.

Pindaan Senarai Racun

2. (1) Senarai Racun yang dinyatakan dalam Jadual Pertama kepada Akta Racun 1952, yang disebut “Akta ibu” dalam Perintah ini, dipinda—

- (a) dengan menggantikan butiran “Adenosine; its salts” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Adenosine; its salts	-	-	All preparations unless exempted	-	-	(1) Cosmetics containing not more than 0.3% of Adenosine; its salts (2) Infant formula milk, follow up formula milk containing Adenosine; its salts”;

- (b) dengan memasukkan selepas butiran “Alcuronium chloride” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Alefacept Alemtuzumab	-	-	All preparations All preparations”;			

- (c) dengan memasukkan selepas butiran “Alfuzosin; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Aliskiren	-	-	All preparations”;			

- (d) dengan memasukkan selepas butiran “Anastrozole” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Anidulafungin	-	-	All preparations”;			

- (e) dengan memasukkan selepas butiran “L-Asparaginase” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Atazanavir	-	-	All preparations”;			

- (f) dengan memasukkan selepas butiran “Bethanidine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Bevacizumab	-	All preparations”;				

- (g) dengan memasukkan selepas butiran “Boric acid and Sodium borate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Bortezomib	-	All preparations”;				

- (h) dengan memasukkan selepas butiran “Buprenorphine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Bupropion	-	All preparations”;				

- (i) dengan memasukkan selepas butiran “Butinoline; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Butoconazole	-	All preparations unless in Group C	Pessaries. Preparations for external use”;			

- (j) dengan menggantikan butiran “Caffeine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Caffeine	-	-	-	-	All preparations unless exempted	Food, beverages and cosmetics containing caffeine”;

- (k) dengan memasukkan selepas butiran “Cetorelix” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Cetuximab	-	All preparations”;				

- (l) dengan menggantikan butiran “Clotrimazole” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Clotrimazole	-	All preparations unless in Group C or exempted	Pessaries	-	-	Preparations containing clotrimazole as a single ingredient for external use”;

- (m) dengan memasukkan selepas butiran “Dapsone and other substances structurally derived therefrom; their salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Darunavir	-	All preparations				
Dasatinib	-	All preparations”;				

- (n) dengan memasukkan selepas butiran “Decamethonium; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Deferasirox	-	All preparations”;				

- (o) dengan memasukkan selepas butiran “Ectylurea” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Efalizumab	-	All preparations”;				

- (p) dengan memasukkan selepas butiran “Entacapone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Entecavir	-	All preparations”;				

- (q) dengan memasukkan selepas butiran “Eperisone; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Eplerenone	-	All preparations”;				

- (r) dengan memasukkan selepas butiran “Eptifibatide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Erlotinib	-	All preparations”;				

- (s) dengan memasukkan selepas butiran “Etryptamine; its salts (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Everolimus	-	All preparations”;				

- (t) dengan memasukkan selepas butiran “Exemestane” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Exenatide	-	All preparations”;				

- (u) dengan memasukkan selepas butiran “Frusemide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Fulvestrant	-	All preparations”;				

- (v) dengan memasukkan selepas butiran “Hypothalamic Hormones and their synthetic analogues” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ibandronic Acid	-	All preparations”;				

- (w) dengan memasukkan selepas butiran “Idrocilamide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Iloprost	-	All preparations”;				

- (x) dengan memasukkan selepas butiran “Imidapril HCl” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Imiglucerase	-	All preparations”;				

- (y) dengan memasukkan selepas butiran “Itraconazole” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Ivabradine	-	All preparations”;				

- (z) dengan memasukkan selepas butiran “Lansoprazole” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Lanthanum	-	All preparations				
Lapatinib	-	All preparations”;				
Ditosylate						

- (aa) dengan memasukkan selepas butiran “Lumefantrine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Lumiracoxib	-	All preparations”;				

- (bb) dengan memasukkan selepas butiran “Miglitol” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Milnacipran	-	All preparations”;				

- (cc) dengan memasukkan selepas butiran “Neostigmine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nepafenac	-	-	All preparations”;			

(dd) dengan memasukkan selepas butiran “Nicardipine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nicotinic acid	-	Sustained release preparations containing nicotinic acid	-	-	-	All preparations unless in Group B”;

(ee) dengan memasukkan selepas butiran “Nikethamide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nilotinib	-	All preparations”;				

(ff) dengan memasukkan selepas butiran “Olanzapine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Olmesartan medoxomil	-	All preparations				
Omalizumab	-	All preparations”;				

(gg) dengan memasukkan selepas butiran “Pecazine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Pegabtanib Sodium	-	All preparations				
Pegfilgrastim	-	All preparations				
Pegvisomant	-	All preparations”;				

(hh) dengan memasukkan selepas butiran “Radium and other radioactive substances for therapeutic use” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Raltegravir	-	All preparations”;				

- (ii) dengan memasukkan selepas butiran “Ramipril” dan butir-butir yang berhubungannya dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ranibizumab	-	All preparations”;				

- (jj) dengan memasukkan selepas butiran “Rasburicase” dan butir-butir yang berhubungannya dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Rebamipide	-	All preparations”;				

- (kk) dengan memasukkan selepas butiran “Rimiterol; its salts” dan butir-butir yang berhubungannya dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Rimonabant	-	All preparations”;				

- (ll) dengan memasukkan selepas butiran “Rosuvastatin” dan butir-butir yang berhubungannya dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Rotigotine	-	All preparations”;				

- (mm) dengan memasukkan selepas butiran “Sertaconazole; its salts” dan butir-butir yang berhubungannya dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sertindole	-	All preparations”;				

(nn) dengan menggantikan butiran “Sex Hormones-androgenic, oestrogenic and progestational, natural or synthetic” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sex Hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following: Benzoestrol Derivatives of stilbene or naphthalene with oestrogenic activity; their esters Steroid compounds with androgenic, oestrogenic or progestational activity; their esters	-	(1) All preparations with androgenic properties unless in Group C or exempted (2) Progestational preparations for subdermal implant	All preparations unless in Group B or exempted	-	-	Preparations for external use containing not more than 40 ppm of oestrogenic substances”;

(oo) dengan memasukkan selepas butiran “Sirolimus” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sitagliptin	-	All preparations”;				

(pp) dengan memasukkan selepas butiran “Somatostatin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sorafenib	-	All preparations”;				

(qq) dengan memasukkan selepas butiran “Sumatriptan; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sunitinib maleate	-	All preparations”;				

- (rr) dengan memasukkan selepas butiran “Tegaserod” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Telbivudine	-	-	All preparations”;			

- (ss) dengan memasukkan selepas butiran “Tropisetron; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Tropium chloride	-	-	All preparations”;			

- (tt) dengan memasukkan selepas butiran “Vardenafil” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Varenicline tartrate	-	All preparations”;				

- (uu) dengan memasukkan selepas butiran “Vigabatrin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Vildagliptin	-	All preparations”;				

- (vv) dengan memasukkan selepas butiran “Zaleplon” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Zanamivir	-	All preparations”;		dan		

- (ww) dengan memasukkan selepas butiran “Ziprasidone Hydrochloride Monohydrate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Zofenopril calcium	-	All preparations”;				

(2) Lampiran kepada Senarai Racun yang dinyatakan dalam Akta ibu dipinda—

- (a) dalam senarai “Analgesics including antipyretic and anti-inflammatory agents:”—
 - (i) dengan memasukkan selepas butiran “Lanazolac; its salts” butiran “Lumiracoxib”; dan
 - (ii) dengan memasukkan selepas butiran “Nefopam; its salts” butiran “Nepafenac”;
- (b) dalam senarai “Antidepressants:”—
 - (i) dengan memasukkan selepas butiran “Amitriptyline; its salts” butiran “Bupropion”;
 - (ii) dengan memasukkan selepas butiran “Mianserin; its salts” butiran “Milnacipran”; dan
 - (iii) dengan memasukkan selepas butiran “Protriptyline; its salts” butiran “Sertindole”;
- (c) dalam senarai “Antidiabetic:”—
 - (i) dengan memasukkan selepas butiran “Chlorpropamide; its salts” butiran “Exenatide”;
 - (ii) dengan memasukkan selepas butiran “Rosiglitazone; its salts” butiran “Sitagliptin”; dan
 - (iii) dengan memasukkan selepas butiran “Tolcyclamide” butiran “Vildagliptin”;
- (d) dalam senarai “Antifungals and Antiprotozoals:”—
 - (i) dengan memasukkan selepas butiran “Amorolfine” butiran “Anidulafungin”; dan
 - (ii) dengan memasukkan selepas butiran “Bifonazole” butiran “Butoconazole”;
- (e) dalam senarai “Antihypertensives:”—
 - (i) dengan memasukkan sebelum butiran “Alseroxylon” butiran “Aliskiren”;
 - (ii) dengan memasukkan selepas butiran “Nitrendipine” butiran “Olmesartan medoxomil”; dan
 - (iii) dengan memasukkan selepas butiran “Veratrum, alkaloids of” butiran “Zofenopril calcium”;
- (f) dalam senarai “Antineoplastic agents and Immunosuppressants:”—
 - (i) dengan memasukkan sebelum butiran “Aminopterin” butiran “Alemtuzumab”;
 - (ii) dengan memasukkan selepas butiran “Basiliximab” butiran “Bevacizumab”;

-
- (iii) dengan memasukkan selepas butiran “Bicalutamide” butiran “Bortezomib”;
 - (iv) dengan memasukkan selepas butiran “Carmustine; its salts” butiran “Cetuximab”;
 - (v) dengan memasukkan selepas butiran “Dacliximab” butiran “Dasatinib”;
 - (vi) dengan memasukkan selepas butiran “Docetaxel” butiran “Erlotinib”;
 - (vii) dengan memasukkan selepas butiran “Emestane” butiran “Everolimus”;
 - (viii) dengan memasukkan selepas butiran “Fotemustine” butiran “Fulvestrant”;
 - (ix) dengan memasukkan selepas butiran “Irinotecan; its salts” butiran “Lapatinib Ditosylate”;
 - (x) dengan memasukkan selepas butiran “Mycophenolic acid” butiran “Nilotinib”;
 - (xi) dengan memasukkan selepas butiran “Pemetrexed” butiran yang berikut:
 - “Penclovir
 - Raltegravir”;
 - (xii) dengan memasukkan selepas butiran “Sirolimus” butiran “Sorafenib”; dan
 - (xiii) dengan memasukkan selepas butiran “Streptozocin” butiran “Sunitinib maleate”;
- (g) dalam senarai “Antiparkinsonism agents:”, dengan memasukkan selepas butiran “Ropinirole” butiran “Rotigotine”;
- (h) dalam senarai “Anti-ulcer agents:”, dengan memasukkan selepas butiran “Ranitidine its salts” butiran “Rebamipide”;
- (i) dalam senarai “Antiviral agents:”—
- (i) dengan memasukkan selepas butiran “Amantadine and other substances structurally derived therefrom; their salts” butiran yang berikut:
 - “Atazanavir
 - Darunavir”;
 - (ii) dengan memasukkan selepas butiran “Efavirenz” butiran “Entecavir”;
 - (iii) dengan memasukkan selepas butiran “Stuvudine; its salts” butiran “Telbivudine”; dan
 - (iv) dengan memasukkan selepas butiran “Zalcitabine” butiran “Zanamivir”;

- (j) dalam senarai “Cardio drugs:”—
- (i) dengan memasukkan selepas butiran “Dofetilide” butiran “Eplerenone”; dan
 - (ii) dengan memasukkan selepas butiran “Flecainide; its salts” butiran “Ivabradine”; dan
- (k) dalam senarai “Miscellaneous:”—
- (i) dengan memasukkan selepas butiran “Adefovir Dipivoxil” butiran “Alefacept”;
 - (ii) dengan memasukkan selepas butiran “Danazol” butiran “Deferasirox”;
 - (iii) dengan memasukkan selepas butiran “Dutasteride” butiran “Efalizumab”;
 - (iv) dengan memasukkan selepas butiran “Hydrogen cyanide; metal cyanides other than ferrocyanides and ferricyanides” butiran yang berikut:
 - “Ibandronic Acid
 - Iloprost”;
 - (v) dengan memasukkan selepas butiran “Imatinib” butiran “Imiglucerase”;
 - (vi) dengan memasukkan selepas butiran “Latanoprost” butiran “Lanthanum”;
 - (vii) dengan memasukkan selepas butiran “Nux Vomica, alkaloids of” butiran “Omalizumab”;
 - (viii) dengan memasukkan selepas butiran “Pamidronate disodium” butiran yang berikut:
 - “Pegabtanib Sodium
 - Pegfilgrastim
 - Pegvisomant”;
 - (xi) dengan memasukkan selepas butiran “Radium and other radioactive substances for therapeutic use” butiran “Ranibizumab”;
 - (xii) dengan memasukkan selepas butiran “Riluzole” butiran “Rimonabant”;
 - (xiii) dengan memasukkan selepas butiran “Tropisetron; its salts” butiran “Tropium chloride”; dan
 - (xiv) dengan memasukkan selepas butiran “Valganciclovir” butiran “Varenicline tartrate”.

Dibuat 21 Julai 2008
[KK(R)608(14); PN(PU²)172/IX]

DATO' LIOW TIONG LAI
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2008

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Poisons List) Order 2008**.

Amendment of Poisons List

2. (1) The Poisons List as set out in the First Schedule to the Poisons Act 1952, which is referred to as the “principal Act” in this Order, is amended—

(a) by substituting for the item “Adenosine; its salts” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Adenosine; its salts	-	-	All preparations unless exempted	-	-	(1) Cosmetics containing not more than 0.3% of Adenosine; its salts (2) Infant formula milk, follow up formula milk containing Adenosine; its salts”;

(b) by inserting after the item “Alcuronium chloride” and the particulars relating to it the following items:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Alefacept	-	All preparations				
Alemtuzumab	-	All preparations”;				

- (c) by inserting after the item “Alfuzosin; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Aliskiren	-	All preparations”;				

- (d) by inserting after the item “Anastrozole” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Anidulafungin	-	All preparations”;				

- (e) by inserting after the item “L-Asparaginase” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Atazanavir	-	All preparations”;				

- (f) by inserting after the item “Bethanidine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Bevacizumab	-	All preparations”;				

- (g) by inserting after the item “Boric acid and Sodium borate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Bortezomib	-	All preparations”;				

- (h) by inserting after the item “Buprenorphine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Bupropion	-	All preparations”;				

- (i) by inserting after the item “Butinoline; its salts” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Butoconazole	-	All preparations unless in Group C	Pessaries. Preparations for external use”;			

- (j) by substituting for the item “Caffeine” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Caffeine	-	-	-	-	All preparations unless exempted	Food, beverages and cosmetics containing caffeine”;

- (k) by inserting after the item “Cetrorelix” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Cetuximab	-	All preparations”;				

- (l) by substituting for the item “Clotrimazole” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Clotrimazole	-	All preparations unless in Group C or exempted	Pessaries	-	-	Preparations containing clotrimazole as a single ingredient for external use”;

- (m) by inserting after the item “Dapsone and other substances structurally derived therefrom; their salts” and the particulars relating to it the following items:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Darunavir	-	All preparations				
Dasatinib	-	All preparations”;				

- (n) by inserting after the item “Decamethonium; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Deferasirox	-	All preparations”;				

- (o) by inserting after the item “Ectylurea” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Efalizumab	-	All preparations”;				

- (p) by inserting after the item “Entacapone” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Entecavir	-	All preparations”;				

- (q) by inserting after the item “Eperisone; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Eplerenone	-	All preparations”;				

- (r) by inserting after the item “Eptifibatide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Erlotinib	-	All preparations”;				

- (s) by inserting after the item “Etryptamine; its salts (DD)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Everolimus	-	All preparations”;				

- (t) by inserting after the item “Exemestane” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Exenatide	-	All preparations”;				

- (u) by inserting after the item “Frusemide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Fulvestrant	-	All preparations”;				

- (v) by inserting after the item “Hypothalamic Hormones and their synthetic analogues” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ibandronic Acid	-	All preparations”;				

- (w) by inserting after the item “Idroclamide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Iloprost	-	All preparations”;				

- (x) by inserting after the item “Imidapril HCl” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Imiglucerase	-	All preparations”;				

- (y) by inserting after the item “Itraconazole” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ivabradine	-	All preparations”;				

- (z) by inserting after the item “Lansoprazole” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Lanthanum	-	All preparations				
Lapatinib	-	All preparations”;				
Ditosylate						

- (aa) by inserting after the item “Lumefantrine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Lumiracoxib	-	All preparations”;				

- (bb) by inserting after the item “Miglitol” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Milnacipran	-	All preparations”;				

- (cc) by inserting after the item “Neostigmine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nepafenac	-	-	All preparations”;			

- (dd) by inserting after the item “Nicardipine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nicotinic acid	-	Sustained release preparations containing nicotinic acid	-	-	-	All preparations unless in Group B”;

- (ee) by inserting after the item “Nikethamide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nilotinib	-	All preparations”;				

(ff) by inserting after the item “Olanzapine” and the particulars relating to it the following items:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Olmesartan medoxomil	-	All preparations				
Omalizumab	-	All preparations”;				

(gg) by inserting after the item “Pecazine; its salts” and the particulars relating to it the following items:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Pegabtanib Sodium	-	All preparations				
Pegfilgrastim	-	All preparations				
Pegvisomant	-	All preparations”;				

(hh) by inserting after the item “Radium and other radioactive substances for therapeutic use” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Raltegravir	-	All preparations”;				

(ii) by inserting after the item “Ramipril” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Ranibizumab	-	All preparations”;				

(jj) by inserting after the item “Rasburicase” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Rebamipide	-	All preparations”;				

(kk) by inserting after the item “Rimiterol; its salts” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Rimonabant	-	All preparations”;				

- (ll) by inserting after the item “Rosuvastatin” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Rotigotine	-	All preparations”;				

- (mm) by inserting after the item “Sertaconazole; its salts” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sertindole	-	All preparations”;				

- (nn) by substituting for the item “Sex Hormones-androgenic, oestrogenic and progestational, natural or synthetic” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sex Hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following: Benzoestrol Derivatives of stilbene or naphthalene with oestrogenic activity; their esters Steroid compounds with androgenic, oestrogenic or progestational activity; their esters	-	(1) All preparations with androgenic properties unless in Group C or exempted (2) Progestational preparations for subdermal implant	All preparations unless in Group B or exempted	-	-	Preparations for external use containing not more than 40 ppm of oestrogenic substances”;

- (oo) by inserting after the item “Sirolimus” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sitagliptin	-	All preparations”;				

(pp) by inserting after the item “Somatostatin” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sorafenib	-	All preparations”;				

(qq) by inserting after the item “Sumatriptan; its salts” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Sunitinib maleate	-	All preparations”;				

(rr) by inserting after the item “Tegaserod” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Telbivudine	-	All preparations”;				

(ss) by inserting after the item “Tropisetron; its salts” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Tropium chloride	-	-	All preparations”;			

(tt) by inserting after the item “Vardenafil” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Varenicline tartrate	-	-	All preparations”;			

(uu) by inserting after the item “Vigabatrin” and the particulars relating to it the following item:

Names	Part I				Part II	Exempt
	Group A	Group B	Group C	Group D		
“Vildagliptin	-	All preparations”;				

- (vv) by inserting after the item “Zaleplon” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Zanamivir	-	All preparations”; and				

- (ww) by inserting after the item “Ziprasidone Hydrochloride Monohydrate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Zofenopril calcium	-	All preparations”.				

(2) The Appendix to the Poisons List as set out in the principal Act is amended—

- (a) under the list of “Analgesics including antipyretic and anti-inflammatory agents:”—

- (i) by inserting after the item “Lanazolac; its salts” the item “Lumiracoxib”; and
- (ii) by inserting after the item “Nefopam; its salts” the item “Nepafenac”;

- (b) under the list of “Antidepressants:”—

- (i) by inserting after the item “Amitriptyline; its salts” the item “Bupropion”;
- (ii) by inserting after the item “Mianserin; its salts” the item “Milnacipran”; and
- (iii) by inserting after the item “Protriptyline; its salts” the item “Sertindole”;

- (c) under the list of “Antidiabetic:”—

- (i) by inserting after the item “Chlorpropamide; its salts” the item “Exenatide”;
- (ii) by inserting after the item “Rosiglitazone; its salts” the item “Sitagliptin”; and
- (iii) by inserting after the item “Tolcyclamide” the item “Vildagliptin”;

- (d) under the list of “Antifungals and Antiprotozoals:”—

- (i) by inserting after the item “Amorolfine” the item “Anidulafungin”; and
- (ii) by inserting after the item “Bifonazole” the item “Butoconazole”;

-
- (e) under the list of “Antihypertensives:”—
- (i) by inserting after the item “Alseroxylon” the item “Aliskiren”;
 - (ii) by inserting after the item “Nitrendipine” the item “Olmesartan medoxomil”; and
 - (iii) by inserting after the item “Veratrum, alkaloids of” the item “Zofenopril calcium”;
- (f) under the list of “Antineoplastic agents and Immunosuppressants:”—
- (i) by inserting before the item “Aminopterin” the item “Alemtuzumab”;
 - (ii) by inserting after the item “Basiliximab” the item “Bevacizumab”;
 - (iii) by inserting after the item “Bicalutamide” the item “Bortezomib”;
 - (iv) by inserting after the item “Carmustine; its salts” the item “Cetuximab”;
 - (v) by inserting after the item “Dacliximab” the item “Dasatinib”;
 - (vi) by inserting after the item “Docetaxel” the item “Erlotinib”;
 - (vii) by inserting after the item “Emestane” the item “Everolimus”;
 - (viii) by inserting after the item “Fotemustine” the item “Fulvestrant”;
 - (ix) by inserting after the item “Irinotecan; its salts” the item “Lapatinib Ditosylate”;
 - (x) by inserting after the item “Mycophenolic acid” the item “Nilotinib”;
 - (xi) by inserting after the item “Pemetrexed” the following items:
 - “Penciclovir
 - Raltegravir”;
 - (xii) by inserting after the item “Sirolimus” the item “Sorafenib”;
 - and
 - (xiii) by inserting after the item “Streptozocin” the item “Sunitinib maleate”;
- (g) under the list of “Antiparkinsonism agents:”, by inserting after the item “Ropinirole” the item “Rotigotine”;
- (h) under the list of “Anti-ulcer agents:”, by inserting after the item “Ranitidine; its salts” the item “Rebamipide”;

(i) under the list of “Antiviral agents:”—

- (i) by inserting after the item “Amantadine and other substances structurally derived therefrom; their salts” the following items:

“Atazanavir

Darunavir”;

- (ii) by inserting after the item “Efavirenz” the item “Entecavir”;
- (iii) by inserting after the item “Stuvudine; its salts” the item “Telbivudine”; and
- (iv) by inserting after the item “Zalcitabine” the item “Zanamivir”;

(j) under the list of “Cardio drugs:”—

- (i) by inserting after the item “Dofetilide” the item “Eplerenone”;
- and
- (ii) by inserting after the item “Flecainide; its salts” the item “Ivabradine”; and

(k) under the list of “Miscellaneous:”—

- (i) by inserting after the item “Adefovir Dipivoxil” the item “Alefacept”;
- (ii) by inserting after the item “Danazol” the item “Deferasirox”;
- (iii) by inserting after the item “Dutasteride” the item “Efalizumab”;
- (iv) by inserting after the item “Hydrogen cyanide; metal cyanides other than ferrocyanides and ferricyanides” the following items:
- “Ibandronic Acid
- Iloprost”;
- (v) by inserting after the item “Imatinib” the item “Imiglucerase”;
- (vi) by inserting after the item “Latanoprost” the item “Lanthanum”;
- (vii) by inserting after the item “Nux Vomica, alkaloids of” the item “Omalizumab”;
- (viii) by inserting after the item “Pamidronate disodium” the following items:
- “Pegabtanib Sodium
- Pegfilgrastim
- Pegvisomant”;

- (ix) by inserting after the item “Radium and other radioactive substances for therapeutic use” the item “Ranibizumab”;
- (x) by inserting after the item “Riluzole” the item “Rimonabant”;
- (xi) by inserting after the item “Tropisetron; its salts” the item “Trospium chloride”; and
- (xii) by inserting after the item “Valganciclovir” the item “Varenicline tartrate”.

Made 21 July 2008
[KK(R)608(14); PN(PU²)172/IX]

DATO' LIOW TIONG LAI
Minister of Health

P.U. (A) 280.

AKTA INSTITUSI KEWANGAN PEMBANGUNAN 2002

PERINTAH INSTITUSI KEWANGAN PEMBANGUNAN (INSTITUSI YANG DITETAPKAN)
(PENGECUALIAN) (PINDAAN) 2008

PADA menjalankan kuasa yang diberikan oleh seksyen 122 Akta Institusi Kewangan Pembangunan 2002 [*Akta 618*], Menteri, atas syor Bank, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Institusi Kewangan Pembangunan (Institusi yang Ditetapkan) (Pengecualian) (Pindaan) 2008**.

Pindaan perenggan 3

2. Perenggan 3 Perintah Institusi Kewangan Pembangunan (Institusi yang Ditetapkan) (Pengecualian) 2007 [*P.U. (A) 424/2007*] dipinda dengan menggantikan perkataan “Institusi” dengan perkataan “Kecuali berhubung dengan pengecualian yang diberikan kepada Bank Pertanian Malaysia bagi tahun kewangan yang berakhir pada 31 Disember 2007 yang tidak tertakluk kepada apa-apa syarat, institusi”.

Dibuat 29 Julai 2008
[BNM/JUN/DFI; PN(PU²)625/II]

TAN SRI NOR MD BIN YAKCOP
Menteri Kewangan Kedua

DEVELOPMENT FINANCIAL INSTITUTIONS ACT 2002

DEVELOPMENT FINANCIAL INSTITUTIONS (PRESCRIBED INSTITUTIONS)
(EXEMPTION) (AMENDMENT) ORDER 2008

In exercise of the powers conferred by section 122 of the Development Financial Institutions Act 2002 [*Act 618*], the Minister, on the recommendation of the Bank, makes the following order:

Citation

1. This order may be cited as the **Development Financial Institutions (Prescribed Institutions) (Exemption) (Amendment) Order 2008**.

Amendment of paragraph 3

2. Paragraph 3 of the Development Financial Institutions (Prescribed Institutions) (Exemption) Order 2007 [*P.U. (A) 424/2007*] is amended by substituting for the word “The” the words “Except in relation to the exemption granted to Bank Pertanian Malaysia for the financial year ending on 31 December 2007 which is not subject to any conditions, the”.

Made 29 July 2008
[BNM/JUN/DFI; PN(PU²)625/II]

TAN SRI NOR MD BIN YAKCOP
Second Minister of Finance

P.U. (A) 281.

AKTA ZON BEBAS 1990

PERATURAN-PERATURAN ZON BEBAS (PINDAAN) 2008

PADA menjalankan kuasa yang diberikan oleh seksyen 47 Akta Zon Bebas 1990 [*Akta 438*], Menteri membuat peraturan-peraturan yang berikut:

Nama

1. Peraturan-peraturan ini bolehlah dinamakan **Peraturan-Peraturan Zon Bebas (Pindaan) 2008**.

Pindaan peraturan 4

2. Peraturan-Peraturan Zon Bebas 1991 [*P.U. (A) 321/1991*] dipinda dalam subperaturan 4(2)—

- (a) dengan menggantikan perkataan “dan” selepas perkataan “Stulang Laut dalam daerah Johor Bahru, Johor” dengan koma; dan

- (b) dengan memasukkan selepas perkataan “Bukit Kayu Hitam dalam daerah Kubang Pasu, Kedah” perkataan “dan Mukim Rantau Panjang, Jajahan Pasir Mas, Kelantan”.

Dibuat 12 Ogos 2008

[SULIT KE.HT(96)966/01-1; Perb. (C)0.217/28(6); PN(PU²)485/V]

TAN SRI NOR MD BIN YAKCOP
Menteri Kewangan Kedua

FREE ZONES ACT 1990

FREE ZONES (AMENDMENT) REGULATIONS 2008

IN exercise of the powers conferred by section 47 of the Free Zones Act 1990 [Act 438], the Minister makes the following regulations:

Citation

1. These regulations may be cited as the **Free Zones (Amendment) Regulations 2008**.

Amendment of regulation 4

2. The Free Zones Regulations 1991 [*P.U. (A) 321/1991*] are amended in subregulation 4(2)—

- (a) by substituting for the word “and” after the words “Stulang Laut in the district of Johor Bahru, Johor” a comma; and
- (b) by inserting after the words “Bukit Kayu Hitam in the district of Kubang Pasu, Kedah” the words “and Mukim of Rantau Panjang, District of Pasir Mas, Kelantan”.

Made 12 August 2008

[SULIT KE.HT(96)966/01-1; Perb. (C)0.217/28(6); PN(PU²)485/V]

TAN SRI NOR MD BIN YAKCOP
Second Minister of Finance

P.U. (A) 282.

AKTA CUKAI JUALAN 1972

PERINTAH CUKAI JUALAN (PENGECUALIAN) (PINDAAN) (No. 4) 2008

PADA menjalankan kuasa yang diberikan oleh seksyen 8 Akta Cukai Jualan 1972 [*Akta 64*], Menteri membuat perintah yang berikut:

Nama dan permulaan kuat kuasa

1. (1) Perintah ini bolehlah dinamakan **Perintah Cukai Jualan (Pengecualian) (Pindaan) (No. 4) 2008**.

(2) Perintah ini mula berkuat kuasa pada 22 Ogos 2008.

Pindaan Jadual B

2. Perintah Cukai Jualan (Pengecualian) 2008 [*P.U. (A) 91/2008*] dipinda dalam Jadual B berhubung dengan butiran 78 dalam ruang (2)—

- (a) dengan memasukkan koma bernoktah di hujung subbutiran (ix); dan
- (b) dengan memasukkan selepas subbutiran (ix) subbutiran yang berikut:

(2)

Persons

“(x) Syarikat Perbadanan Urusan Kejuruteraan dan Limbungan Brooke (Brooke Dockyard and Engineering Works Corporation) Kuching, Sarawak;

(xi) Syarikat Kencana HL Sdn. Bhd.”.

Pembatalan

3. Perintah Cukai Jualan (Pengecualian) (Pindaan) (No. 2) 2008 [*P.U. (A) 125/2008*] dibatalkan.

Dibuat 18 Ogos 2008

[6 SULIT KE.HE(96)669/13-66 S.K.36; Perb. (8.20)116/5/1-16440 Vol. 8; PN(PU²)102/XVI]

TAN SRI NOR MD BIN YAKCOP
Menteri Kewangan Kedua

SALES TAX ACT 1972

SALES TAX (EXEMPTION) (AMENDMENT) (NO. 4) ORDER 2008

IN exercise of the powers conferred by section 8 of the Sales Tax Act 1972 [*Act 64*], the Minister makes the following order:

Citation and commencement

1. (1) This order may be cited as the **Sales Tax (Exemption) (Amendment) (No. 4) Order 2008**.

(2) This Order comes into operation on 22 August 2008.

Amendment of Schedule B

2. The Sales Tax (Exemption) Order 2008 [*P.U. (A) 91/2008*] is amended in Schedule B in relation to item 78 in column (2)—

(a) by inserting a semi colon at the end of subitem (ix); and

(b) by inserting after subitem (ix) the following subitems:

(2)

Persons

“(x) Syarikat Perbadanan Urusan Kejuruteraan dan Limbungan Brooke (Brooke Dockyard and Engineering Works Corporation) Kuching, Sarawak;

(xi) Syarikat Kencana HL Sdn. Bhd.”.

Revocation

3. The Sales Tax (Exemption) (Amendment) (No. 2) Order 2008 [*P.U. (A) 125/2008*] is revoked.

Made 18 August 2008

[6 SULIT KE.HE(96)669/13-66 S.K.36; Perb. (8.20)116/5/1-16440 Vol. 8; PN(PU²)102/XVI]

TAN SRI NOR MD BIN YAKCOP
Second Minister of Finance

Hakcipta Pencetak (H)

PERCETAKAN NASIONAL MALAYSIA BERHAD

Semua Hak Terpelihara. Tiada mana-mana bahagian jua daripada penerbitan ini boleh diterbitkan semula atau disimpan di dalam bentuk yang boleh diperolehi semula atau disiarkan dalam sebarang bentuk dengan apa jua cara elektronik, mekanikal, fotokopi, rakaman dan/atau sebaliknya tanpa mendapat izin daripada Percetakan Nasional Malaysia Berhad (Pencetak kepada Kerajaan Malaysia yang dilantik).



DICETAK OLEH
PERCETAKAN NASIONAL MALAYSIA BERHAD,
KUALA LUMPUR
BAGI PIHAK DAN DENGAN PERINTAH KERAJAAN MALAYSIA